Millions of patients in the U.S. are in need of a new generation of drugs to treat a wide range of infectious and chronic diseases.  The companies that produce a preponderance of these new drugs have been hard hit by the economic downturn, by burdensome and costly Federal regulations and by the lack of private venture capital.  SHR works closely with our clients for access to scarce funding, the development of cooperative research agreements, visibility to decision-makers and more. 



SHR Scope of Services

  • Create support and funding vehicle for drug development

  • Advance client therapies and products by offering strategic guidance based upon our intimate knowledge and contacts within federal agencies and Congress

  • Arrange meetings with Members and senior congressional staff, federal officials and others to maximize opportunities for our clients  

  • Develop white papers and information pieces that integrate with client objectives

  • Relocation analyses to ensure the best economic arrangements for clients 

  • Create legislative and regulatory vehicles and remedies

  • Identify and respond to opportunities and funding for collaborative research and development 

  • Manage advocacy for new federally facilitated drug development